Summary

The 7 major epithelial ovarian cancer markets reached a value of US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.3 Billion by 2034, exhibiting a growth rate (CAGR) of 18.2% during 2024-2034.

The epithelial ovarian cancer market has been comprehensively analyzed in IMARC's new report titled "Epithelial Ovarian Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Epithelial ovarian cancer, also referred to as ovarian carcinoma, is a type of cancer that originates from the epithelial cells that line the outer surface of the ovaries. It often presents with nonspecific symptoms, which can make early disease detection a bit challenging. Some of the common indications associated with the ailment include abdominal bloating or discomfort, pelvic pain or pressure, changes in bowel or bladder habits, feeling full quickly while eating, unexplained weight loss, fatigue, changes in menstrual cycles, etc. Diagnosing epithelial ovarian cancer typically involves a combination of medical history assessment, physical examination, imaging tests, and tissue sampling. The process begins with a thorough evaluation of the patient's symptoms, medical history, and risk factors. A pelvic examination may be performed to check the condition of the ovaries. Numerous imaging procedures, such as transvaginal ultrasound, CT scan, MRI, etc., are used to visualize the ovaries and assess the extent of the disease. A biopsy is usually conducted to confirm the diagnosis, which helps to determine the type of ovarian cancer, its grade, and its stage. Additionally, genetic testing may be recommended to identify inherited gene mutations that could influence treatment decisions and guide genetic counseling.

The increasing cases of inherited gene mutations, particularly in the BRCA1 and BRCA2 genes, that disrupt the DNA repair process and lead to an accumulation of genetic errors, are primarily driving the epithelial ovarian cancer market. Besides this, the rising prevalence of several associated risk factors, such as long-term use of estrogen-only hormone replacement therapy, endometriosis, family history, obesity, etc., is creating a positive outlook for the market. Furthermore, the escalating usage of hormone therapy, which involves the use of medications that either block the production of hormones or interfere with their action, thereby slowing down the development of tumor, is also bolstering the market growth. Apart from this, the emerging popularity of intraperitoneal chemotherapy, since it delivers the chemotherapy drugs directly into the abdominal cavity and allows for higher drug concentrations in the area where ovarian cancer is most likely to spread, is acting as another significant growth-inducing factor. Moreover, the ongoing advancements in surgical techniques, including the introduction of precision-guided surgery and sentinel lymph node mapping, which aim to improve the extent of tumor removal while preserving healthy tissue and achieving optimal debulking, are expected to drive the epithelial ovarian cancer market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the epithelial ovarian cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for epithelial ovarian cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the epithelial ovarian cancer market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the epithelial ovarian cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the epithelial ovarian cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current epithelial ovarian cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the epithelial ovarian cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the epithelial ovarian cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the epithelial ovarian cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of epithelial ovarian cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of epithelial ovarian cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of epithelial ovarian cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with epithelial ovarian cancer across the seven major markets?
What is the size of the epithelial ovarian cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of epithelial ovarian cancer?
What will be the growth rate of patients across the seven major markets?

Epithelial Ovarian Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for epithelial ovarian cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the epithelial ovarian cancer market?
What are the key regulatory events related to the epithelial ovarian cancer market?
What is the structure of clinical trial landscape by status related to the epithelial ovarian cancer market?
What is the structure of clinical trial landscape by phase related to the epithelial ovarian cancer market?
What is the structure of clinical trial landscape by route of administration related to the epithelial ovarian cancer market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Epithelial Ovarian Cancer - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Epithelial Ovarian Cancer - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Epithelial Ovarian Cancer - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 Epithelial Ovarian Cancer - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Epithelial Ovarian Cancer - Unmet Needs

10 Epithelial Ovarian Cancer - Key Endpoints of Treatment

11 Epithelial Ovarian Cancer - Marketed Products
11.1 List of Epithelial Ovarian Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Lynparza (Olaparib) - AstraZeneca
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rubraca (Rucaparib) - Clovis Oncology
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Zejula (Niraparib) - Janssen/Merck/GlaxoSmithKline
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Avastin (Bevacizumab) - Genentech/Roche
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Elahere (Mirvetuximab soravtansine) - ImmunoGen
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Epithelial Ovarian Cancer - Pipeline Drugs
12.1 List of Epithelial Ovarian Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 MK-1775 - AstraZeneca
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 IMNN 001 - Imunon
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ITIL306 - Instil Bio
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 DPX Survivac - ImmunoVaccine Technologies
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Epithelial Ovarian Cancer - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Epithelial Ovarian Cancer – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Epithelial Ovarian Cancer - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Epithelial Ovarian Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Epithelial Ovarian Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Epithelial Ovarian Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Epithelial Ovarian Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Epithelial Ovarian Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Epithelial Ovarian Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Epithelial Ovarian Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Epithelial Ovarian Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Epithelial Ovarian Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Epithelial Ovarian Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Epithelial Ovarian Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Epithelial Ovarian Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Epithelial Ovarian Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Epithelial Ovarian Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Epithelial Ovarian Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Epithelial Ovarian Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview

16 Epithelial Ovarian Cancer - Recent Events and Inputs From Key Opinion Leaders

17 Epithelial Ovarian Cancer Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Epithelial Ovarian Cancer Market – Strategic Recommendations

19 Appendix